SINOVAC Biotech (SVA) announced it has prevailed against Advantech/Prime Success’ Petition for Emergency Injunctive Relief in the U.S. District Court for the Southern District of New York. The result in the New York court represents another failure in the campaign by Advantech/Prime in coordination with Vivo Capital to wrest control of SINOVAC from its recently installed, lawfully-elected Board of Directors in accordance with the Privy Council order and Antiguan Law, and to interfere with the payment of the US$55.00 per common share special cash dividend declared by the current SINOVAC Board.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SVA:
- Sinovac Biotech Announces Special Shareholder Meeting Amid Governance Changes
- Sinovac Biotech Announces Strategic Dividend and Governance Initiatives Amid Hostile Takeover Attempt
- Sinovac Biotech accelerates payment of $55 per share special cash dividend
- SAIF Partners files proxy materials in connection with Sinovac Biotech meeting
- Heng Ren urges Sinovac board to pay $55 cash dividend before July 8 vote